Search results for "Lability"

showing 10 items of 802 documents

Per-flow signalling extension across DiffServ domains

2003

This paper describes a framework devised to extend per-flow admission control operation across Differentiated Services domains. Although the specific case of interoperability with RSVP is under discussion, our proposal can be easily adapted to other hop-by-hop signalling protocols. In our framework, DiffSery border routers accomplish three tasks. First, during the set-up phase, flows are mapped onto PHB groups on the basis of their QoS and traffic specifications. Second, signalling packets are tunnelled into IP packets marked as “probes”, where the “probe” marking is a DCSP value associated to the considered PHB Group. Third, when the flow set-up is complete, flow data packets are marked as…

Differentiated servicesComputer scienceNetwork packetbusiness.industryQuality of serviceComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSInteroperabilityScalabilityProvisioningAdmission controlbusinessComputer networkCall blocking
researchProduct

On the Ball-Marsden-Slemrod obstruction for bilinear control systems

2019

International audience; In this paper we present an extension to the case of $L^1$-controls of a famous result by Ball--Marsden--Slemrod on the obstruction to the controllability of bilinear control systems in infinite dimensional spaces.

Discrete mathematics010102 general mathematics01 natural sciences010101 applied mathematicsControllabilityAlgebraBilinear controlOptimization and Control (math.OC)Settore MAT/05FOS: MathematicsBall (mathematics)[MATH.MATH-OC]Mathematics [math]/Optimization and Control [math.OC]0101 mathematicsMathematics - Optimization and ControlMathematics::Symplectic GeometryMathematics
researchProduct

Hoffman's Error Bound, Local Controllability, and Sensitivity Analysis

2000

Our aim is to present sufficient conditions ensuring Hoffman's error bound for lower semicontinuous nonconvex inequality systems and to analyze its impact on the local controllability, implicit function theorem for (non-Lipschitz) multivalued mappings, generalized equations (variational inequalities), and sensitivity analysis and on other problems like Lipschitzian properties of polyhedral multivalued mappings as well as weak sharp minima or linear conditioning. We show how the information about our sufficient conditions can be used to provide a computable constant such that Hoffman's error bound holds. We also show that this error bound is nothing but the classical Farkas lemma for linear …

Discrete mathematicsMaxima and minimaControllabilityLinear inequalityControl and OptimizationApplied MathematicsErgodicityVariational inequalityApplied mathematicsConstant (mathematics)Farkas' lemmaImplicit function theoremMathematicsSIAM Journal on Control and Optimization
researchProduct

Controllability method for acoustic scattering with spectral elements

2007

We formulate the Helmholtz equation as an exact controllability problem for the time-dependent wave equation. The problem is then discretized in time domain with central finite difference scheme and in space domain with spectral elements. This approach leads to high accuracy in spatial discretization. Moreover, the spectral element method results in diagonal mass matrices, which makes the time integration of the wave equation highly efficient. After discretization, the exact controllability problem is reformulated as a least-squares problem, which is solved by the conjugate gradient method. We illustrate the method with some numerical experiments, which demonstrate the significant improveme…

DiscretizationHelmholtz equationApplied MathematicsNumerical analysisSpectral element methodMathematical analysisSpectral element methodFinite difference methodExact controllabilityFinite element methodControllabilityakustinen sirontaComputational MathematicsMass lumpingHelmholtz equationSpectral methodMathematicsJournal of Computational and Applied Mathematics
researchProduct

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Codeine Phosphate

2014

The present monograph reviews data relevant to applying the biowaiver procedure for the approval of immediate-release multisource solid dosage forms containing codeine phosphate. Both biopharmaceutical and clinical data of codeine were assessed. Solubility studies revealed that codeine meets the "highly soluble" criteria according to World Health Organization (WHO), the European Medicines Agency (EMA), and the United States Food and Drug Administration (US FDA). Codeine's fraction of dose absorbed in humans was reported to be high (>90%) based on cumulative urinary excretion of drug and drug-related material following oral administration. The permeability of codeine was also assessed to be …

Dosage FormsDrugCodeinebusiness.industrymedia_common.quotation_subjectCodeinePharmaceutical ScienceCodeine PhosphateBioequivalencePharmacologyDosage formBioavailabilityExcipientsBiopharmaceuticalSolubilityOral administrationmedicineHumansbusinessmedicine.drugmedia_commonJournal of Pharmaceutical Sciences
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate

2021

Sitagliptin is an antihyperglycemic drug used in adults for the treatment of diabetes Type 2. Literature data and in-house experiments were applied in this monograph to assess whether methods based on the Biopharmaceutics Classification System (BCS) could be used to assess the bioequivalence of solid immediate-release (IR) oral dosage forms containing sitagliptin phosphate monohydrate, as an alternative to a pharmacokinetic study in human volunteers. The solubility and permeability characteristics of sitagliptin were reviewed according to the BCS, along with dissolution, therapeutic index, therapeutic applications, pharmacokinetics, pharmacodynamic characteristics, reports of bioequivalence…

Dosage FormsDrugbusiness.industrymedia_common.quotation_subjectSitagliptin PhosphateAdministration OralBiological AvailabilityPharmaceutical SciencePharmacologyBioequivalenceBiopharmaceutics Classification SystemPermeabilityDosage formBiopharmaceuticsBioavailabilitySolubilityTherapeutic EquivalencyPharmacokineticsSitagliptinPharmacodynamicsmedicineHumansbusinessmedicine.drugmedia_commonJournal of Pharmaceutical Sciences
researchProduct

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Ketoprofen

2012

Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate-release (IR) solid oral dosage forms containing ketoprofen are reviewed. Ketoprofen's solubility and permeability, its therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions, and reported BE/bioavailability (BA)/dissolution data were taken into consideration. The available data suggest that according to the current Biopharmaceutics Classification System (BCS) and all current guidances, ketoprofen is a weak acid that would be assigned to BCS Class II. The extent of ketoprofen abso…

Dosage FormsKetoprofenChromatographyChemistryChemistry PharmaceuticalAdministration OralBiological AvailabilityPharmaceutical ScienceExcipientBioequivalenceBiopharmaceutics Classification SystemPermeabilityDosage formAbsorptionBioavailabilityExcipientsstomatognathic diseasesSolubilityTherapeutic EquivalencyPharmacokineticsKetoprofenmedicineHumansSolubilitymedicine.drugJournal of Pharmaceutical Sciences
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam.

2015

Literature and experimental data relevant for the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing levetiracetam are reviewed. Data on solubility and permeability suggest that levetiracetam belongs to class I of the biopharmaceutical classification system (BCS). Levetiracetam's therapeutic use, its wide therapeutic index, and its favorable pharmacokinetic properties make levetiracetam a valid candidate for the BCS-based biowaiver approach. Further, no BE studies with levetiracetam IR formulations in which the test formulation failed to show BE with the comparator have been reported in the open lit…

Dosage FormsSolid oral dosage formLevetiracetamChemistryChemistry PharmaceuticalPharmaceutical ScienceBiological AvailabilityPharmacologyBioequivalencePiracetamDosage formPermeabilityBiopharmaceuticsReference productBiopharmaceuticalTherapeutic EquivalencymedicineAnimalsHumansAnticonvulsantsLevetiracetamImmediate releasemedicine.drugJournal of pharmaceutical sciences
researchProduct

Core-Shell Arginine-Containing Chitosan Microparticles for Enhanced Transcorneal Permeation of Drugs

2019

Chitosan oligosaccharide (C) was functionalized with L-arginine (A) and short hydrocarbon chains (C-8) to design an amphiphilic copolymer, henceforth CAC(8), leading to microparticles (MPs) consisting of an arginine-decorated hydrophilic shell and inner hydrophobic domains allowing the encapsulation of high amount hydrophobic drugs such as sorafenib tosylate (>10% w/w). L-arginine side chains were selected in order to impart the final MPs enhanced transcorneal penetration properties, thus overcoming the typical biological barriers which hamper the absorption of drugs upon topical ocular administration. The mucoadhesive properties and drug release profile of the CAC(8) MPs (CAC(8)-MPs) were …

Drug3003congenital hereditary and neonatal diseases and abnormalitiesArginineSwinemedia_common.quotation_subjectamphiphilic copolymerPharmaceutical ScienceL-arginineAdministration Ophthalmic02 engineering and technologyArginine030226 pharmacology & pharmacyCorneaChitosan03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineMucoadhesionSide chainAnimalsskin and connective tissue diseasesProtein Kinase Inhibitorsmedia_commonMucin-3microparticlesDrug CarriersMucinnutritional and metabolic diseasesSorafenibPermeation021001 nanoscience & nanotechnologyCombinatorial chemistryBioavailabilityDrug LiberationmicroparticlechemistrySettore CHIM/09 - Farmaceutico Tecnologico Applicativoocular administrationchitosan0210 nano-technologymucoadhesion
researchProduct

The Influence of Single-Dose and Short-Term Administration of Quercetin on the Pharmacokinetics of Midazolam in Humans.

2015

Quercetin is a plant flavonol that is available from both daily diet and nutraceuticals. To investigate the effect of acute and short-term intake of high-dose quercetin on CYP3A-mediated metabolism, 10 healthy volunteers received 7.5 mg oral midazolam without, with a single dose of 1500 mg quercetin and after 1-week supplementation with 1500 mg quercetin daily. A substudy was performed in three subjects to explore the impact of repeated quercetin intake on intravenously administered midazolam. Coadministration with a single dose of quercetin did not significantly alter the pharmacokinetics of midazolam and its 1'-hydroxymetabolite, but following short-term quercetin intake, there was a tren…

DrugAdultMalemedia_common.quotation_subjectMidazolamPharmaceutical ScienceAdministration OralPharmacologychemistry.chemical_compoundPharmacokineticsmedicineCytochrome P-450 CYP3AHumansheterocyclic compoundsDrug InteractionsAdverse effectmedia_commonCross-Over StudiesbiologyCytochrome P450MetabolismBioavailabilitychemistryArea Under Curvebiology.proteinMidazolamAdministration IntravenousFemaleQuercetinQuercetinmedicine.drugJournal of pharmaceutical sciences
researchProduct